Shafique Virani - 01 Jun 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
01 Jun 2023
Net transactions value
-$374,034
Form type
4
Filing time
05 Jun 2023, 18:29:44 UTC
Previous filing
17 May 2023
Next filing
20 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $214,500 -25,000 -13% $8.58 161,819 01 Jun 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale $159,534 -17,865 -11% $8.93 143,954 02 Jun 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2 Includes 1,717 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023.